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Abstract

Author Manuscript

Schizophrenia is a serious mental illness, involving disruptions in thought and behavior, with a
worldwide prevalence of about one percent. Although highly heritable, much of the genetic
liability of schizophrenia is yet to be explained. We searched for susceptibility loci in multiplex,
multigenerational families affected by schizophrenia, targeting protein-altering variation with in
silico predicted functional effects. Exome sequencing was performed on 136 samples from eight
European-American families, including 23 individuals diagnosed with schizophrenia or
schizoaffective disorder. In total, 11,878 non-synonymous variants from 6,396 genes were tested
for their association with schizophrenia spectrum disorders. Pathway enrichment analyses were
conducted on gene-based test results, protein-protein interaction (PPI) networks, and epistatic
effects. Using a significance threshold of FDR<0.1, association was detected for rs10941112
(P=2.1×10−5; q-value=0.073) in AMACR, a gene involved in fatty acid metabolism and previously
implicated in schizophrenia, with significant cis effects on gene expression (P=5.5×10−4),
including brain tissue data from the Genotype-Tissue Expression project (minimum P=6.0×10−5).
A second SNP, rs10378 located in TMEM176A, also shows risk effects in the exome data
(P=2.8×10−5; q-value=0.073). Protein-protein interactions among our top gene-based association
results (P<0.05; n=359 genes) reveal significant enrichment of genes involved in NCAM-mediated
neurite outgrowth (P=3.0×10−5), while exome-wide SNP-SNP interaction effects for rs10941112
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and rs10378 indicate a potential role for kinase-mediated signaling involved in memory and
learning. In conclusion, these association results implicate AMACR and TMEM176A in
schizophrenia risk, whose effects may be modulated by genes involved in synaptic plasticity and
neurocognitive performance.
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INTRODUCTION
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Schizophrenia is a debilitating mental disorder characterized by psychosis, cognitive
impairment and neurophysiological features, often involving social and occupational
dysfunction, with increased physical health problems and shorter lifespans [Mueser and
McGurk, 2004]. The onset of symptoms generally occurs in early adulthood, affecting
approximately 1% of individuals globally [van Os and Kapur, 2009], with substantial
burdens on national healthcare systems and economies. The rate of sustained recovery is
modest, as pharmacological treatments are of limited efficacy for functional outcome and
cognitive performance [Miyamoto et al., 2012], underscoring our need for greater
understanding of schizophrenia’s pathophysiological mechanisms.
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Although a substantial genetic underpinning has been incontrovertibly demonstrated in twin,
family and adoption studies, yielding heritability estimates of around 0.80 [Sullivan et al.,
2003], much of the genetic liability of schizophrenia remains to be accounted for [Lee et al.,
2012]. Linkage screens, candidate gene studies, and genome-wide association studies
(GWAS) have implicated various genetic loci in schizophrenia risk, like the major
histocompatibility complex (MHC) region at locus 6p22, suggesting a highly polygenic
architecture with potentially thousands of variants, both common and rare, mostly of small
effect [Purcell et al., 2009].
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To meet this challenge, some researchers have turned to next generation sequencing to
comprehensively interrogate genetic variation from across the genome for disease
association. Coupled with appropriate filtering protocols, this approach has led to the
discovery of novel susceptibility genes for many traits, especially for Mendelian conditions
[Ng et al., 2010]. For more complex traits such as neuropsychiatric disorders, etiological
insights have been gained, including the impact of de novo or rare mutational loads on
schizophrenia risk [Girard et al., 2011], with disruptive variants showing enrichment among
genes involved in calcium ion channels and post-synaptic complexes [Fromer et al., 2014].
Despite the mounting evidence of a polygenic burden, the identification of schizophrenia
risk genes in population-based sequencing studies has been hindered by statistical power
issues related to small effect sizes, even with the increasing enormity of the data sets.
However, Timms et al. [2013] achieved a notable success in unraveling schizophrenia
genetics by targeting multiplex families (i.e., with several schizophrenic individuals).
Examining whole exome sequence variation, the authors reported on the co-segregation of
rare, protein-altering variants in N-methyl-D-aspartate (NMDA) receptor genes, lending
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2018 December 01.
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support for the glutamatergic hypofunction hypothesis of schizophrenia. A more limited
look at exome sequence variants within a previously implicated linkage region in multiplex
families implicated AMPA receptor trafficking, which also ties into glutamatergic function
[Kos et al., 2016].
In this paper, we conduct exome sequencing in eight multiplex, multigenerational EuropeanAmerican families, including 23 individuals diagnosed with schizophrenia or schizoaffective
disorder, in an effort to uncover new susceptibility genes and further our understanding of
the biological basis of schizophrenia spectrum disorders. Through association testing and
pathway enrichment analysis, we identify protein-altering variants in genes involved in fatty
acid metabolism as potential risk factors, representing novel targets for schizophrenia
treatment and research.

Author Manuscript

MATERIALS AND METHODS
Family Samples

Author Manuscript
Author Manuscript

From eight pedigrees ascertained for the Multiplex-Multigenerational Genetic Investigation
of Schizophrenia (MGI) study [Almasy et al., 2008], samples from 136 individuals were
exome sequenced, ranging from 6 to 26 individuals per family, including 21 diagnosed with
schizophrenia and two cases of schizoaffective disorder of the depressed type (SAD), based
on DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria.
Ages range from 15 to 86 years (mean=48.8, SD=19.8), with 44.9% male. Among the
affected individuals, comorbidity included substance abuse and dependence (alcohol,
amphetamines; n=7 cases), antisocial personality disorder, mild mental retardation, and
mood disorder. The selection of samples to be sequenced was based on various criteria,
foremost being affection status and its pedigree density, availability and quality of DNA
samples, and extremity of neurocognitive measures, in particular, the Penn Conditional
Exclusion Test (PCET) that assesses abstraction and mental flexibility, features that are
mediated by synaptic plasticity and often compromised in schizophrenia [Kos et al., 2016].
Among the eight families chosen for our study, a mean of four individuals per family
(SD=1.20) were diagnosed with schizophrenia or SAD (mean for the other MGI families is
approximately 2.2, SD=0.48), which includes the most densely affected family with six
cases. Mean PCET efficiency scores for the 136 study samples is −0.50 (SD=1.19), which is
significantly more dysfunctional than the mean score for the MGI samples not selected
(−0.21, SD=1.03; P=8.9×10−3), including other members belonging to the eight target
pedigrees (0.10, SD=0.98; P=3.0×10−4). The European-American families from MGI were
originally recruited through a proband diagnosed with schizophrenia, with at least one firstdegree relative affected with schizophrenia or SAD. All first-, second- and third-degree
relatives of 15 years of age or older were invited to participate. The study was approved by
the Institutional Review Board of each of the collaborating institutions (University of
Pennsylvania, University of Pittsburgh, and Texas Biomedical Research Institute), with
informed consent obtained from all participants after receiving a complete description of the
study, and parental consent required for minors.
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DSM-IV diagnoses were achieved through a consensus of the following: 1) Diagnostic
Interview for Genetics Studies, v. 2.0; 2) Family Interview for Genetics Studies; and 3)
reviews of available medical records. For each subject, lifetime best-estimate diagnoses were
determined by two investigators that include both psychiatrists and psychologists, each blind
to the familial relationships of the participants. Cases involving psychotic features, as well as
any discrepancies between the two raters, were further reviewed, with inter-rater reliability
at kappa >0.8. In total, 106 individuals from 43 multi-generational families were diagnosed
with schizophrenia or SAD. At the time of assessment, 75% of cases were undergoing
treatment, including anti-psychotics. In addition to schizophrenia, other psychiatric
conditions were identified in the MGI families, including personality disorders,
schizoaffective disorder bipolar type, and delusional disorder.
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Penn Conditional Exclusion Test (PCET)
To evaluate neurocognitive performance, MGI participants underwent a computerized test
battery [Gur et al., 2001a,b]. Abstraction and mental flexibility were assessed using the
PCET [Kurtz et al., 2004], requiring participants to select one of four shapes for exclusion
based on a sorting principle. An efficiency score was calculated as the average z score for
performance accuracy and speed.
Exome Sequencing
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Exome sequencing was performed on 136 samples using the Illumina TruSeq platform on
the HiSeq 2000 (Illumina, San Diego, CA), yielding approximately 62 megabases (Mb) of
sequence data per sample, with uniform coverage of 201,121 exons from 20,794 genes (for
more details, see Supplementary Methods). Using CASAVA 1.8 suite, FASTQ files of demultiplexed paired sequencing reads of 100 bp were produced, which were mapped to the
UCSC human genome reference assembly 19 (hg19) with BWA (v. 0.6.1) [Li and Durbin,
2009]. To ensure consistency, the mapped reads were analyzed with SAMtools (v. 0.1.12a)
[Li et al., 2009] and Picard (v. 1.56) [http://picard.sourceforge.net] to mark likely PCR
duplicates. The sequence data were then genotype called and filtered for quality with the
GATK (v. 1.6) software package [McKenna et al., 2010], with recalibrated confidence scores
greater than or equal to Q30, and assigned variant quality scores (VQS) based on covarying
sequence annotations (e.g., quality score normalized by allele depth, haplotype score, strand
bias, and mapping quality). The output was 380,895 single nucleotide polymorphisms
(SNPs) in VCF format, with functional annotation achieved with ANNOVAR (v.
2013Feb21) [Wang et al., 2010]. Non-synonymous variants with potential deleterious effects
on protein function, as predicted by the algorithms SIFT (scores > 0.95; categorized as
“damaging”) and/or PolyPhen2 (scores >0.15; categorized as either “probably damaging” or
“possibly damaging”), are the focus of the study. In total, 11,878 variants were selected,
with VQS LOD ≥4.0, 100% call rate, and Hardy-Weinberg Equilibrium P-values >0.001
(computed in SOLAR).
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Five missense variants were selected for follow-up genotyping: rs10941112 (AMACR) and
rs10378 (TMEM176A), both of which show significant association with schizophrenia in
our discovery data set, and three SNPs from the gene AMACR, rs2278008, rs2287939, and
rs34677, two of which have been previously implicated in schizophrenia risk. In total, 456
individuals from 41 families were genotyped, with 49.3% male and ranging in age from 15
to 87 years (mean=45.1, SD=16.7), including 64 individuals diagnosed with schizophrenia
or SAD (n=6), with a mean of 1.41 cases (SD=0.95) per family (range: 1–3). Genotyping
was performed using the TaqMan allelic discrimination methodology on a Life Technologies
QuantStudio 12K Flex instrument. Assays included a combination of pre-designed TaqMan
SNP Genotyping assays and custom TaqMan SNP Assays designed using the Custom
TaqMan Assay Design Tool. Assays were prepared in a 384-well plate in a final volume of
5uL and PCR performed on the QuantStudio as per the manufacturer’s protocol. Genotype
data was analyzed and results exported using the TaqMan Genotyper Software on the
QuantsStudio 12K Flex system.
GWAS Data from the Psychiatric Genomics Consortium

Author Manuscript

Significant SNP association results from the exome sequence data were compared to the
most recent GWAS data generated for schizophrenia by the Psychiatric Genomics
Consortium (PGC) [Ripke et al., 2014]. The study involved meta-analysis of 49 case control
samples and 3 family based association studies (up to 36,989 cases and 113,075 controls in
total), predominantly of European ancestry, testing approximately 9.5 million SNPs after
quality control and imputation. Diagnoses were determined with DSM-IV or ICD-10 (10th
revision of the International Statistical Classification of Diseases and Related Health
Problems) criteria.
mRNA Profiling
Gene expression data were examined for AMACR and TMEM176A, the genes harboring the
significant association signals observed at rs10941112 and rs10378, respectively. RNA
transcription levels were assayed in 107 study samples from lymphoblastoid cell lines using
the Illumina HT-12 Expression BeadChips, with preliminary data analysis performed using
Illumina GenomeStudio Software. Raw signals were log transformed and standardized by zscoring within individuals (cell lines) to reduce the influence of inter-individual differences
stemming from variation in RNA quality. For each transcript, an inverse Gaussian
transformation was performed on the residual expression scores prior to association testing
(see below).
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Data from the Genotype-Tissue Expression (GTEx) project, a comprehensive atlas of
correlations between genotypes and tissue-specific gene expression levels [The GTEx
Consortium, 2013], were also examined for SNPs significantly associated with
schizophrenia in the MGI samples. GTEx donors (n=544) of any sex, race, and ethnic group
are identified through low-post-mortem-interval (PMI) autopsy or organ and tissue
transplant settings. Biospecimens for 53 tissue types are quantified for gene expression from
massively parallel sequencing of RNA. Peripheral blood samples are collected and used as a
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source for whole-genome SNP and copy number variant (CNV) genotyping, and to establish
lymphoblastoid cell lines.
Statistical Analysis

Author Manuscript

Genetic association tests and heritability (h2) estimation were performed using the program
SOLAR [Almasy and Blangero, 1998], based on maximum likelihood variance
decomposition methods. Associations between protein-altering variants and diagnoses of
schizophrenia and SAD, as well as PCET efficiency scores and gene expression data, were
examined via measured genotype analyses (MGA), under a liability threshold model for
discrete traits. This is a mixed effects variance components approach in which kinship
relations are treated as random effects, parameterized by additive genetic variation (i.e.,
residual heritability), with SNPs defined as fixed effects. The likelihoods of models saturated
for the effects of both kinship and SNP genotypes were compared to null models with SNP
effects constrained to zero, representing a single degree of freedom test. P-values were
adjusted using the tail-area based False Discovery Rate (FDR) approach, with q-values
estimated using the fdrtool package in R. SNPs with q-values <0.1, a threshold considered as
statistically significant, were also evaluated for cis effects on gene expression. Covariates
included sex, age, age squared, and their interactions. Pairwise genetic interactions were
investigated by expanding MGA models to include main effects of a secondary SNP
genotype and its interaction with rs10941112 or rs10378.
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Gene-based association tests were performed in the software KGG v. 4.0 using GATES, an
extended Simes test that combines P-values of SNPs within a gene to obtain an overall Pvalue (Benjamini-Hochberg correction), which has shown robust power for detecting genes
with one or a few independent causal variants [Li et al., 2011]. Gene annotation was
achieved in KGG using the RefGene database, with SNP LD based on 1000 Genomes
haplotypes for European population samples. Pathway enrichment was assessed among top
associated genes (GATES P<0.01; n=87 genes) by conducting Fisher’s exact tests on these
observed results, as well as permuted data representing 100,000 similar-sized gene lists
randomized from 7,300 genes annotated to the 11,878 target SNPs, yielding empirical Pvalues, adjusted with the Bonferroni approach. Pathways defined by KEGG, Biocarta,
Pathway Interaction Database (PID) and Reactome (n=1,273) were used in the enrichment
analyses. Protein-protein interactions were also investigated among the top associated genes
(GATES P<0.05; n=359 genes) using the web resource STRING v. 10.0, based on curated
experimental data from primary interaction sources, reporting on results with PPI confidence
scores greater than 0.40 [Szklarczyk et al., 2015].

Author Manuscript

RESULTS
Exome Sequence Data
From the targeted 62 Mb, exome sequencing yielded an average of 35 reads per nucleotide
variant, with an average of 88,922 SNPs called per individual (Table 1). In total, 380,895
SNPs were identified, with approximately half (50.6%) displaying derived (i.e., nonancestral) allele frequencies < 5.0%, and a novelty rate of 21.8% relative to dbSNP 137
(note: GATK quality metrics available in supplementary Figures S1 and S2). The transition:
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transversion (Ti:Tv) ratio is 2.03, consistent with ratios reported for genome-wide sequence
data, although markedly less than the 3.0–3.5 range generally observed for exonic variation
[DePristo et al., 2011]. When broken down according to genic location and function, 26.9%
of the sequence variants are exonic, of which 57.1% are rare and uncommon (frequencies <
5.0%), and a Ti:Tv ratio of just 2.70, likely reflecting the presence of false positives and/or
unknown sequencing context bias [DePristo et al., 2011]. To better control for Type I errors,
we applied stringent filters on the exonic variants, retaining 57,684 autosomal SNPs with
VQS LOD ≥ 4.0 and no missing genotypes, as well as excluding any de novo mutations,
producing a Ti:Tv ratio of 3.41. From this subset, 11,878 missense variants with potential
deleterious effects were identified using the SIFT and PolyPhen2 scores (minimum
MAF=0.0074), which are the focus of this association study.
Association Results for Schizophrenia Risk

Author Manuscript
Author Manuscript

The top ten association results for schizophrenia (h2=0.84±0.78; P=8.6×10−3) are presented
in Table 2. Genomic inflation is observed (λ=1.28, Q-Q plot presented in Figure S3),
however given the nature of the targeted sequence data (i.e., deleterious missense mutations
with intragenic LD) and the high heritability and polygenic architecture of schizophrenia
[Purcell et al., 2009], this is not unexpected [Yang et al., 2011]. The top association
(P=2.10×10−5) is for a common SNP (MAF=0.39), rs10941112 (nucleotide transition
G524A; amino acid substitution G175D), located in exon 3 in the gene AMACR at locus
5p13 (Figure 1), with the minor G allele showing evidence of decreased susceptibility (β=
−0.97±0.45), which is significant after adjustment using the FDR approach (q-value=0.073).
All 23 of the affected individuals are carriers of the risk allele, A, with 18 homozygotes and
5 heterozygotes, producing an inflated allele frequency of 89.1% among cases. This starkly
contrasts the 113 unaffected members, with a genotype ratio of 37:50:26 for AA: AG: GG,
corresponding to a frequency of 54.9% for the A allele. Based on 1000 Genomes data, the
risk allele ranges in frequency from 3.3% to 51.5% for African and European populations,
respectively. Precomputed scores of the Combined Annotation-Dependent Deletion (CADD)
algorithm, a “meta-annotation” tool for assessing the effects of mutations on protein
function [Kircher et al., 2014], ranks rs10941112 in the top 0.063% of the most deleterious
SNPs among the 8.6 billion possible substitutions in the hg19 human reference genome.
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AMACR (UniProtKB Accession #: Q9UHK6) codes a key enzyme in the metabolism of
fatty acids and bile acids derived from cholesterol, and has been previously implicated in
schizophrenia [Bespalova et al., 2010], in particular the SNPs rs2278008 (P=0.51) and
rs2287939 (P=0.13). To further characterize the association signal at rs10941112, we phased
the haplotype structure of rs10941112, rs2278008, and rs2287939, as well as the missense
variant rs34677 in exon 4 (G556T; V186F; MAF=0.17), whose minor allele exhibits a
significant protective effect on schizophrenia risk (β=−0.73±0.63; P=0.021) and was
excluded from the 11,878 protein-altering variants selected for analysis because SIFT and
PolyPhen2 scores were not assigned by ANNOVAR (note: SIFT score from the Variant
Effect Predictor tool on the Ensembl website predicts damaging effects). In total, nine
haplotypes were identified, with a significant association with schizophrenia observed for
the major haplotype (f=0.57; P=0.0036; β=−0.73±0.63), which harbors the rs10941112 risk
allele (supplementary Table S1).
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The next best signal is for the common SNP rs10378 (P=2.80×10−5; MAF=0.18) in the
transmembrane protein gene TMEM176A (Figure S4; UniProtKB Accession #: Q96HP8),
which also yielded a q-value of 0.073, with increased risk for the minor T allele
(β=1.14±0.53), with a CADD score in the top 0.25% (G561T; L187F). Among affected
individuals, a ratio of 3:15:7 is observed for genotypes TT: TG: GG, corresponding to an
inflated frequency of 0.42 for the risk allele relative to the 0.15 estimated for European
populations (1000 Genomes); whereas a skewed ratio of 0:31:78 was found for unaffected
members, with a T allele frequency of just 0.14. Of the other SNPs presented in Table 2, all
have q-values of 0.15 or greater, with no prior evidence implicating them in the disorder. At
a permissive P-value of less than 0.01 (n=118 SNPs; supplementary Table S2), no variants
were found to map to any of the well-known schizophrenia candidate risk genes (e.g.,
DISC1, ZNF804A, NRG1, the MHC locus) [Harrison, 2015].

Author Manuscript

In an effort to replicate the significant associations at rs10941112 and rs10378, as well as
investigate three other compelling missense variants within the gene AMACR (rs2278008,
rs2287939, and rs34677), independent MGI samples were genotyped (n=456). No
significant associations were observed in these data, including rs10941112 (P=0.79; β=
−0.022±0.16) and rs10378 (P=0.92; β=0.0015±0.031), with the results found in
supplementary Table S3. Additionally, we examined the PGC GWAS data for schizophrenia
and similarly found no evidence for association at rs10941112 (P=0.80) and rs10378
(P=0.67).
Association Results for PCET

Author Manuscript

Given the deficits in abstraction and mental flexibility observed in the study samples (see
Materials and Methods for selection criteria), we also tested the rs10941112 and rs10378 for
association with PCET efficiency scores (n=105). Both show near significant associations
with the neurocognitive measure (P=0.087 and 0.053, respectively), with their estimated
directions of effect consistent with heightened risk of schizophrenia (β=−0.26±0.29 and
-0.41±0.41, respectively). Not surprisingly, bivariate analyses of schizophrenia and PCET
efficiency revealed highly significant associations at both SNPs (P=5.1×10−5 and 1.81×10−4,
respectively).
mRNA Transcript Analysis

Author Manuscript

For the two significant association signals, rs10941112 and rs10378, we tested for cis effects
on mRNA expression in lymphoblastoid cell lines. We detected a highly significant
association between rs10941112 and the primary transcript of AMACR (RefSeq ID:
NM_014324), with carriers of the disease risk allele showing increased expression levels
(β=0.18±0.10; P=5.53×10−4), and transcript levels showing association with schizophrenia
in our MGI families (β=1.08±0.73; P=3.95×10−3). Three other AMACR missense SNPs
were also examined (supplementary Table S4), with rs34677 showing a significant
association with expression (P=6.84×10−3). As for rs10378, no significant effect was
detected for TMEM176A transcript levels (NM_018487).
Interrogating data from the GTEx project, rs10941112 shows significant association with
AMACR expression in various tissues, with the strongest signal observed for muscle-
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skeletal (n=143; P=2.7×10−18). For GTEx data from twelve different brain regions,
significant associations were detected for seven, including the frontal cortex (n=27; P=0.03;
Figure S5), a region highly implicated in schizophrenia pathology, with the nucleus
accumbens yielding the most significant result (n=30; P=6.0×10−5). In each case,
homozygous risk allele carriers showed increased expression of AMACR, consistent with
our findings from the MGI families.
Pathway Enrichment Tests

Author Manuscript

To search for wider biological patterns in the data, pathway enrichment analyses were
performed on gene-based association results. Genes with P-values < 0.01 for the GATES
association test were selected (n=87), with AMACR (P=2.10×10−5; Benjamini-Hochberg
adjusted P=0.072) and TMEM176A (P=1.40×10−4) representing the top two association
results for schizophrenia (Table S5). Fisher’s exact tests were conducted on these results, as
well as randomized gene lists (100,000X), with the top five enriched pathways all related to
bile acid biosynthesis and peroxisomal lipid metabolism (Table S6; empirical P-values range
from 0.0022 to 0.017; none significant after Bonferroni multiple testing correction),
reflecting the presence of AMACR and HSD17B4 (GATES P=6.24×10−3) in our gene list,
both encoding enzymes involved in these processes.
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We also examined pathway enrichment among protein-protein interaction (PPI) pairs, under
the hypothesis that causal genetic variation affects a limited set of etiological mechanisms
underlying schizophrenia, which are detectable by PPIs. Using the online database STRING
v. 10.0, PPIs were identified for genes among our top GATES association results (nominal P
<0.05; n=359 genes). The nodes (i.e., observed genes) of the resulting PPI network (Figure
S6) were then tested (n=47), revealing significant enrichment after Bonferroni correction in
the Reactome pathway “NCAM Signaling for Neurite Outgrowth” (empirical P=3.0×10−5),
as presented in Table 3.
Lastly, we tested rs10941112 and rs10378 for pairwise interaction effects on schizophrenia
with all the other exome variants examined in this study, revealing no significant effects (top
P=0.12). However, when the top 500 SNP-SNP interactions were analyzed for pathway
enrichment, key brain-related pathways emerged for rs10941112 (Table 4), most notably
mitogen-activated protein kinase (MAPK) signaling (empirical P=2.0×10−4). For rs10738,
regulation of the eIF-4 complex and p70-S6 kinase produced the strongest evidence of
pathway enrichment (empirical P=1.1×10−4; Table S7).

DISCUSSION
Author Manuscript

From whole exome sequences of 136 individuals from eight multiplex families, we have
identified two protein-altering variants that are associated with schizophrenia: rs10941112 in
the gene AMACR and rs10378 in TMEM176A. The product of AMACR, alpha-methylCoA racemase, plays a pivotal role in lipid and bile acid metabolism. AMACR deficiency
(MIM 604489) can lead to the toxic accumulation of metabolic intermediates in tissues and
blood plasma, most notably pristanic acid via the α-oxidation pathway, characterized by
adult onset of neurodegenerative symptoms, including sensory motor neuropathy,
pigmentary retinopathy, seizures, and neurocognitive impairment [Thompson et al., 2007].
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In one documented patient, AMACR deficiency was comorbid with schizophrenia,
displaying elevated plasma pristanic acid levels and neurologic deficits resembling strokelike episodes [Kapina et al., 2010]. Molecular analysis of AMACR identified a homozygous
mutation G559A (G187R) in the patient, which was absent in more than 100 tested controls.
Interestingly, in a separate study, sequence analysis of a trio of AMACR deficiency patients
showed two of the cases as homozygous carriers of the common rs10941112 mutation,
hinting at its potentially damaging effects on enzymatic function [Ferdinandusse et al.,
2000].
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Although rs10941112 is significantly associated with AMACR transcript levels in both our
families (P=5.53×10−4) and GTEx tissue samples (smallest P=2.7×10−18), we hypothesize
that the missense variant does not directly regulate gene expression, but could reflect a
feedback mechanism, whereby increased mRNA levels are triggered through unmetabolized
pristanic acid due to deficient AMACR function, leading to neurodegenerative consequences
and, in some cases, heightened risk for schizophrenia. Studies on the neurotoxic effects of
pristanic acid on rat brain have revealed dramatic Ca2+ dysregulation, impaired aerobic
metabolism, and neural cell death [Busanello et al., 2011]. Moreover, alterations in white
matter have been detected in cases of AMACR deficiency [Clarke et al., 2004], which, along
with deficits in working memory and risk for retinitis pigmentosa, are features shared with
schizophrenia [McDonald et al., 1998; Du et al., 2013].

Author Manuscript

To date, a number of genetic studies of schizophrenia have detected positive linkage signals
and structural changes at locus 5p13, the genomic location of AMACR [Bespalova et al.,
2005; Cooper-Casey et al., 2005]. Based on these findings, as well as the overlapping
symptomatology of AMACR deficiency, Bespalova et al. [2010] identified AMACR as a
candidate for schizophrenia susceptibility, screening its coding and flanking regions in a
multiplex Puerto Rican pedigree. A significant association was observed for a phased
haplotype of rs10941112 and two downstream missense variants, rs2287939 and rs2278008
from exons 4 and 5 (P=3.6×10−5), with increased susceptibility among male carriers. Based
on our exome sequence data, the LD relationship between rs10941112 and other nearby
AMACR variants is relatively weak (Figure 1), with the strongest correlation observed for
rs34677 (r2=0.36), a missense variant in exon 4 that shows modest evidence of association
with schizophrenia (P=0.021). To delineate the signal, we phased the haplotype structure of
rs10941112 and rs34677, as well as the missense SNPs implicated by Bespalova et al.,
revealing a significant association between schizophrenia and the major haplotype harboring
the rs10941112 risk allele (corrected P=0.032).

Author Manuscript

However, despite this compelling evidence, we were not able to replicate the association
signal at rs10941112. GWAS results from the PGC for a large case-control schizophrenia
cohort show no significant association at this locus, nor genotypes that were generated for
independent MGI samples (n=456) for rs10941112 (P=0.79) and other promising SNPs
within AMACR (i.e., rs34677, rs2278008 and rs2287939). If rs10941112 is indeed a risk
variant for schizophrenia, its incomplete penetrance is likely to be influenced by other
genetic factors and their dynamic interactions within broader networks, with its effects
potentially modulated by the polygenic burdens within individual families. Although clearly
underpowered, we probed this hypothesis by testing rs10941112 for pairwise interactions
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with all the other exome variants on affection status, revealing no significant effects (top
P=0.12). However, when the top interactions were then tested for pathway enrichment, some
key brain-related pathways emerged, most notably the top result, mitogen-activated protein
kinase (MAPK) signaling (empirical P=2.0×10−4). This highly conserved signaling cascade
is involved in cell proliferation, differentiation and migration, including neuronal
differentiation and control of synaptic plasticity [Thomas and Huganir, 2004], with some
evidence for its role in the pathophysiology of schizophrenia [Funk et al., 2012].
Interestingly, both lipids and bile acids appear to regulate parts of the pathway, including the
subcellular localization of the MAPK signaling proteins, as well as their kinase activities
[Anderson, 2006; Anwer, 2012].

Author Manuscript
Author Manuscript

It should also be noted that the MGI samples sequenced in this study were selected, in part,
for their extremity in neurocognitive measures, in particular the PCET, which is
compromised among individuals with schizophrenia and their relatives [Kos et al., 2016].
This is borne out in the residuals generated for PCET efficiency scores under the polygenic
model in SOLAR, as the mean for the exome sequence data (−0.29, SD=1.12) is
significantly different from the mean for the genotyped samples (−0.056, SD=0.99; onetailed P=0.019). Interestingly, for our top two results, rs10941112 and rs10378, near
significant associations were observed for PCET efficiency in the exome data (P=0.087 and
0.053, respectively), but not in the follow-up genotype data (P=0.71 and 0.96). This was also
the case for bivariate analysis of PCET and affection status, with significant associations
observed for these two variants in the exome data (P=5.1×10−5 and 1.81×10−4), with a
highly significant negative correlation (r=−0.38; P<2.2×10−16) observed between the
estimated beta coefficients for the two phenotypes for all 11,878 missense SNPs. This
potential neurocognitive dimension of the observed risk effects in our data remains to be
further explored, and may account for the non-replication of rs10941112 and rs10378 in
schizophrenia cohorts not selected in this manner, in addition to the limited power of our
study design. Moreover, lipidomic profiling of pristanic acid and related long-chain fatty
acids in the MGI families and other schizophrenia cohorts will be necessary to establish the
etiological link between AMACR enzymatic dysfunction and schizophrenia risk, as
proposed here.
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As for the association signal at rs10378, this is a novel finding with less supporting evidence
in the existing literature. The missense variant is located in exon 5 of TMEM176A
(supplementary Figure S4), a gene that encodes a transmembrane protein whose function
remains largely unclear, although may have a role in the immune system [Condamine et al.,
2010]. TMEM176A has been implicated in animal models of depression, where a 35-fold
difference in expression levels in cortex and hippocampus was observed between
depression-sensitive and depression-resistant rat lines [Blaveri et al., 2010]. Carriers of the
alternate T allele (transversion G561T; amino acid substitution L187F) in MGI show
increased susceptibility for schizophrenia, however, like rs10941112, this was not replicated
in either the PGC GWAS results or the independent MGI genotype data (P=0.93). The local
LD structure for rs10378 is mostly negligible, with the exception of a lone correlation peak
(r2=0.38) at intronic rs45455308 (P=5.0×10−3 for schizophrenia risk) in the neighboring
gene ABP1, which, notably, codes for an actin-binding protein that controls dendritic spine
morphology and influences synapse formation [Haeckel et al., 2008]. Pairwise interaction
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effects on schizophrenia were again examined, but did not yield any significant effects.
However, pathway analysis of the top results did reveal strong enrichment of genes involved
in the regulation of the eIF-4 complex and p70-S6 kinase (empirical P=1.1×10−4), which
plays a critical role in mRNA translation and synaptic plasticity [Klann et al., 2004], with
the phosphorylation cascade activated by various kinases, including ERK, p38 MAPK and
mTOR [Thomas and Huganir, 2004; Hoeffer and Klann, 2010].
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The link to synaptic plasticity in our data is further underscored by our analysis of PPI pairs
and networks, revealing significant enrichment of genes involved in neural cell adhesion
molecule (NCAM) signaling for neurite outgrowth. NCAM is a transmembrane glycoprotein
of the immunoglobulin superfamily and plays an important role in neural differentiation, as
well as synaptic plasticity, learning and memory [Senkov et al., 2012]. Abnormalities in
NCAM expression have been frequently linked to major psychiatric disorders, including
schizophrenia [Piras et al., 2015].
Conclusion
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From our analysis of whole exome sequence data, we report on two protein-altering SNPs,
rs10941112 and rs10378 from the genes AMACR and TMEM176A, which are significantly
associated with schizophrenia risk in multiplex families, with the former variant also
displaying significant associations with gene expression. AMACR, which has been
previously implicated in schizophrenia, encodes a pivotal enzyme in peroxisomal lipid
oxidation, with deficiencies leading to neurotoxic accumulation of metabolic intermediates,
which have been linked to a variety of neurological problems that manifest in adulthood,
including neurocognitive impairment. Pathway analyses of PPI networks and SNP-SNP
interaction effects reveal enrichment of genes involved in various pathways related to
synaptic plasticity, in particular, kinase phosphorylation cascades known to affect learning
and memory formation, with dysfunction in such pathways implicated in a number of
psychiatric disorders. When tested against a measure of mental flexibility, both SNPs show
near significant associations, indicating a neurocognitive dimension to their putative risk
effects on schizophrenia, which was affirmed through bivariate analyses. Recognizing that
functional improvement in schizophrenia patients will likely require treatment of cognitive
deficits, these findings provide some insight into the potential etiological mechanisms
involved in synaptic plasticity, as well as identify a promising lipid biomarker, pristanic acid,
for enhanced diagnosis and therapeutic intervention that could complement current
pharmacological strategies that largely target neurotransmitter dysfunction.
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Refer to Web version on PubMed Central for supplementary material.
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0.0074

0.0074

0.0074

0.0074

0.015

0.18

0.39

SIFT

Tolerated

Tolerated

Damaging

Damaging

Damaging

Damaging

Damaging

Tolerated

Damaging

Damaging

PolyPhen2

Possibly Damaging

Possibly Damaging

Possibly Damaging

Probably Damaging

Probably Damaging

Probably Damaging

Probably Damaging

Possibly Damaging

Probably Damaging

Possibly Damaging

Beta (SE)

1.55 (0.45)

−4.23 (1.24)

7.24 (2.06)

7.13 (2.03)

7.23 (2.06)

7.13 (2.03)

7.27 (2.07)

4.64 (1.21)

1.14 (0.27)

−0.97 (0.23)

6.26 × 10−4

6.26 × 10−4

4.51 × 10−4

4.51 × 10−4

4.51 × 10−4

4.51 × 10−4

4.51 × 10−4

1.28 × 10−4

2.80 × 10−5*

2.10 × 10−5*

P-Value

False Discovery Rate (FDR) q=0.073.

*

are based on SIFT and PolyPhen2 scores assigned by ANNOVAR.17 Positive beta estimates (standard error in parentheses) for schizophrenia correspond to increased, additive risk for the minor allele
(MA).

Table lists the top ten association results for non-synonymous, potentially damaging exome variants with schizophrenia risk. SNP rs numbers are based on dbSNP build 137. Chromosome (Chrom.) and
position correspond to hg19. Minor allele frequencies (MAFs) are based on maximum likelihood estimates that account for familial relationships. Predicted effects of amino acid changes on protein function

Chrom.

rs10941112

MAF

Author Manuscript

dbSNP 137

Function Prediction

Schizophrenia Risk

Author Manuscript

Top Ten Association Results for Schizophrenia Risk

Author Manuscript
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TABLE 3

Author Manuscript

Pathway Enrichment in Protein-Protein Interactions Determined for Top Association Results (GATES P <
0.05)
Source

No. Observed (%)

Empirical P-value

NCAM Signaling for Neurite Outgrowth

Reactome

4 (6.25)

3.0 × 10−5*

COL2A1, COL4A2, COL9A1, SPTAN1

Developmental Biology

Reactome

6 (1.51)

1.3 × 10−4

COL2A1, COL4A2, COL9A1, SPTAN1,
PPARGC1A, TGS1

NCAM1 Interactions

Reactome

3 (7.69)

2.3 × 10−4

COL2A1, COL4A2, COL9A1

KEGG

4 (2.58)

3.4 ×

10−4

Reactome

2 (3.23)

4.4 × 10−4

HIST1H3A, HIST1H4A

3 (4.00)

10−4

COL2A1, COL9A1, ILK

Enriched Pathway

JAK-STAT Signaling Pathway
RNA Polymerase I Promoter Opening
Alpha-V Beta-3 Integrin Pathway

PID

6.9 ×

Observed Genes

STAT2, IL11RA, IL11, IFNAR1

Author Manuscript

Table presents enriched pathways (empirical P<1.0 × 10−3) in PPI pairs and networks (n=47 nodes) derived for a set of 359 genes representing the
top associations for schizophrenia (GATES P<0.05). PPIs were determined using the online database STRING v. 10.0 (experimental data only, with
confidence scores greater than 0.40). Fisher’s exact tests were permuted 100,000 times for each pathway (n=1,273), with randomized gene lists
drawn from the 7,300 genes tested for association via the GATES method. The four variables in the 2×2 contingency tables are as follows: (1)
number of PPI genes in target pathway; (2) number of PPI genes not in target pathway; (3) number of genes in target pathway not among PPI
genes; and (4) number of genes examined via GATES, excluding genes representing (2) and (3). The sources of the pathways are KEGG, Biocarta,
Pathway Interaction Database (PID), and Reactome.

*

Bonferroni adjusted P=0.038.

Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
Reactome
Biocarta
Reactome

Innate Immune System

Agrin in Postsynaptic Differentiation

Interleukin-1 Signaling

3 (30.0)

5 (41.7)

14 (17.1)

4 (30.8)

10 (19.2)

No. Observed (%)

NRG1, RAPSN, LAMA2, UTRN, PAK6

4.1 × 10−3

NOD1, IRAK4, MAP2K6

NOD1, DEFB129, DAK, DEFB132, ART1, P2RX7, IRAK4, ECSIT, MAP2K6, C8A,
C9, TLR10, CASP8, NLRC5

3.7 × 10−3

8.9 ×

NOD1, IRAK4, ECSIT, MAP2K6

2.6 × 10−3

10−3

MYC, NFATC4, BDNF, ECSIT, MAP2K6, EGF, CACNG6, CACNB2, CACNA1S,
NTRK1

Observed Genes

2.0 × 10−4*

Empirical P-value

Bonferroni adjusted P=0.23.

*

Table presents enriched pathways (empirical P<0.01) for the top 500 pairwise SNP-SNP interaction effects on schizophrenia for rs10941112 (MGA model in SOLAR), with gene annotation determined with
the program ANNOVAR. Fisher’s exact tests were permuted 100,000 times for each pathway (n=1,141), with randomized gene lists drawn from the 6,396 genes mapped to the 11,878 missense variants,
weighted by SNP coverage. The four variables in the 2×2 contingency tables are as follows: (1) number of observed genes (i.e., those harboring SNP-SNP interaction effects, as defined above) in target
pathway; (2) number of observed genes not in target pathway; (3) number of genes in target pathway not among observed genes; and (4) number of genes mapped to the 11,878 variants tested for interaction
effects, excluding genes representing (2) and (3). The sources of the pathways are KEGG, Biocarta, Pathway Interaction Database (PID), and Reactome.

Reactome

KEGG

MAPK Signaling

TRAF6 Mediated Induction of NFKB and Map
Kinases

Source

Enriched Pathway

Pathway Enrichment for Pairwise SNP-SNP Interaction Effects on Schizophrenia for rs10941112 (P<0.01)

Author Manuscript
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